Piramal Pharma (BOM:543635) Accounts Receivable : ₹23,495 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Piramal Pharma's accounts receivables for the quarter that ended in Mar. 2025 was ₹23,495 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Piramal Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2025 was 77.85.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Piramal Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was ₹-30.73.

Piramal Pharma Accounts Receivable Historical Data

The historical data trend for Piramal Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Accounts Receivable Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

Accounts Receivable

8,397.50

17,852.80

17,993.40

21,344.30

23,495.20

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Receivable	Get a 7-Day Free Trial											21,344.30	-	18,271.40	-	23,495.20

Piramal Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Piramal Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Piramal Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	23495.2	/	27540.7	*	91
=	77.85

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Piramal Pharma's accounts receivable are only considered to be worth 75% of book value:

Piramal Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(5766.1	+	0.75 * 23495.2	+	0.5 * 23127	-	75521.2
-	0	-	0)	/	1320.421
=	-30.73

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Piramal Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (BOM:543635) » Definitions » Accounts Receivable

Traded in Other Exchanges

PPLPHARMA:India

Address

Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramalpharma.com

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines